13Jul
10Jul
Regroup Mass Notification Competes in 6th Annual ‘ASTORS’ Awards
Regroup Mass Notification®, which empowers better mass communication to keep people safe and informed during critical and daily events, is delighted to announce its platform has been nominated for the Sixth Consecutive Year in the Annual ‘ASTORS’ Homeland Security Awards Program. Regroup’s easy-to-use system enables administrators to send up to 20,000 voice calls, 65,000 SMS, 100,000 emails, and 540,000 push notifications per minute, rapidly alerting large groups of recipients to danger. Administrators can also expand their reach by distributing messages...
09Jul
The 10 Best Canned Wines of 2022
As time goes the demand for canned wine seems to rise. It saves space, is easy to transport, and doesn’t require any corkscrews or wait for wine glasses to be washed. And the best part is the wine never gets warm. In this article, we will discuss some of the best canned wines From dry red to wines that are crisp with a note of sweetness. There’s something for everyone. Archer Roose Sauvignon Blanc ($59 for 12 cans) - Archer...
08Jul
Myomo Announces Second Quarter Preliminary Revenue and Record Pipeline Additions
Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces preliminary second quarter revenue and provides an update on its pipeline entering the third quarter. Revenue for the second quarter of 2022 is expected to be $3.4 million to $3.6 million, an increase of 10% to 16% compared with the second quarter of 2021. Read more >>
08Jul
FDA Grants Orphan Drug Designation to PBI-200 for NTRK Fusion–Positive Solid Tumors
The FDA has granted an orphan drug designation to PBI-200 for the treatment of patients with NTRK fusion–positive solid tumors, including primary and metastatic brain tumors. PBI-200, which is an oral, highly potent and selective inhibitor of TRK kinase, was designed by Pyramid Biosciences to overcome a wide range of on-target resistance mutations that have been observed with first-generation TRK inhibitors. “Oncogenic NTRK gene fusions are found in a broad range of cancers. Orphan designation for drugs in development such...
01Jul
Top 10 Innovations in Podiatry 2022
Each year, Podiatry Today hears from leaders in the world of foot and ankle medicine and surgery about important developments and significant strides being made in the field. EasyWhip Suture (Winter Innovations) uses a patented two-part needle design to simplify and standardize suture techniques for tendon and ligament reconstruction, according to the company website. Citing speed and quality of stitching as crucial to successful repair, Winter Innovations says EasyWhip is the first suture needle designed to provide both of these...
29Jun
Winning With Talent: Inside Six Boston Tech Companies Hiring Now
Boston is a city of legendary talent. Beantown’s sport legacies, etched along its historic streets, whisper the names of athletes that once called the city home — Brady and Belichick, Bird and Russell, Ruth and Ortiz. Its world-renowned universities have sent recruited emissaries far and wide as intellectual standard-bearers of academic prestige. The fabric of Boston and Cambridge’s historic DNA comprises cutting-edge personnel, weaved together with more than 1,000 biotech companies, from homegrown startups to multinational conglomerates. ...To see how...
29Jun
Vanguard Partners With Candidly For Student Loan Repayment Program
Vanguard has partnered with Candidly to offer retirement plan sponsors a student loan debt repayment program option for eligible employees. The financial wellness service will be available to Vanguard recordkeeping clients as an opt-in feature. Vanguard expects to make the Candidly platform available in the second half of 2022. Workers with student loan debt often have difficulty reaching their financial goals. Financial planning and saving for retirement are complicated, and can be delayed because of student loan debt, says Amber...
29Jun
ZetrOZ Shares Insights for Providers and Patients Seeking Insurance Coverage on Novel Medical Technologies for Advanced Treatments
New medical technologies bring better outcomes to patients and more efficiency to the U.S. healthcare industry, but some insurers and care providers slow its adoption, according to ZetrOZ Systems, a leading innovator and inventor of sustained acoustic medicine for soft tissue injury healing. With more than 100,000 patients treated, George K. Lewis, Ph.D. and CEO of ZetrOZ Systems said, ZetrOZ has learned that a key to winning insurance provider approval of novel medical devices and therapies is thorough advance communication...
29Jun